Innovative Health Initiative (IHI) launched a call for proposals on dealing with pressing challenges in health research and innovation. The funding round covers several topics: ➡ Combating cardiovascular disease in cities ➡ Using big data to make progress on osteoarthritis ➡ Regulatory sandboxes to support breakthrough innovation ➡ Understanding how best to capture patient-centered information Deadline: 10 October 2024 https://hubs.li/Q02FyMWx0 #pharma #lifesciences
Veristat’s Post
More Relevant Posts
-
https://lnkd.in/e-VpTkmV In my previous post, I mentioned the FLOW study demonstrating the beneficial effect of semaglutide on renal outcomes in patients with CKD and diabetes. Today in the late breaking trials session at #EDTA meeting in Stockholm, data were presented showing a significant lower incidence of renal events in obese patients without diabetes. #semaglutide #CKD #obesity #RCT
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial - Nature Medicine
nature.com
To view or add a comment, sign in
-
Manager, Regional Media Relations at AmeriHealth Caritas and Owner, Xperience Matters Marketing. Posts and opinions are my own. Reposts are not endorsements.
Allison Aubrey, NPR news correspondent and contributor, reports that a #drug taken by millions of people to control #diabetes may do more than lower blood sugar. Research suggests #metformin has anti-inflammatory effects that could help protect against common age-related diseases including #heartdisease, #cancer, and #cognitivedecline. Scientists who study the biology of aging have designed a clinical study, known as #TheTAMETrial, to test whether metformin can help prevent these diseases and promote a longer #healthspan in healthy, older adults. Currently the FDA doesn't recognize aging as a disease to treat, but the researchers hope this would usher in a paradigm shift — from treating each age-related medical condition separately, to treating these conditions together, by targeting aging itself. For now, metformin is only approved to treat type 2 diabetes in the U.S., but doctors can prescribe it off-label for conditions other than its approved use. Exciting news...would you try it? Please check with your doctor first before you do.
A cheap drug may slow down aging. A study will determine if it works
npr.org
To view or add a comment, sign in
-
Employer-Sponsored Benefits | Human Capital Management | Data-Driven Decision Making | Process Excellence | MBA
Interesting data released from a new GLP-1 study: 1. Initial clinical findings of 15% weight loss were driven, in part, by lifestyle interventions. The new study still showed an average of 10% sustained weight loss over 208 weeks without these interventions. 2. The study looked at patients who had been using the drug for over 4 years and found no adverse health impacts. 3. Potentially the most interesting finding is that the cardiovascular benefits are not driven by weight loss alone, with the predominant theory being that GLP-1s reduce inflammation in the body driving improved cardiovascular health. #GLP1 #semaglutide #wegovy #weightloss #cardiovascularhealth https://lnkd.in/eBF968Sf
What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
msn.com
To view or add a comment, sign in
-
This review explores the most common noninvasive tests to identify patients with NAFLD who are at risk of adverse outcomes and subsequent clinical management and referral. Read the full Endocrine Practice article!
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics
endocrinepractice.org
To view or add a comment, sign in
-
This review explores the most common noninvasive tests to identify patients with NAFLD who are at risk of adverse outcomes and subsequent clinical management and referral. Read the full Endocrine Practice article!
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics
endocrinepractice.org
To view or add a comment, sign in
-
🌿 I am thrilled to share that our research group has recently published a comprehensive review on the properties and potential therapeutic uses of 1,8-cineole (Eucalyptol), a naturally occurring compound found in botanicals such as eucalyptus, rosemary, and camphor laurel. ✨ 🔍 In Our Review, We Explore: 👉 1,8-cineole’s rich history in traditional medicine exhibiting anti-inflammatory, antioxidant, and antimicrobial properties among others. 👉 Recent evidence supporting its potential role in managing conditions such as Alzheimer’s disease, neuropathic pain, and cancer. 👉 Clinical trials spotlighting its benefits for patients with respiratory disorders like sinusitis, COPD, asthma, and bronchitis 👉 Emerging therapeutic applications in treating ailments including depression, epilepsy, and cardiac-related diseases. Read our full review to dive deep into the advancements in the field and the promising path that lays ahead in utilizing 1,8-cineole in healthcare. 🙏 Grateful for the outstanding support from my mentor Barbara Wollenberg and the incredible team. 🚀 🔗 https://lnkd.in/ecHjKTxW #teamwork #1_8Cineole #eucalyptol #naturalremedies #respiratorydisease #antiinflammatory #antioxidant #antimicrobial
1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
sciencedirect.com
To view or add a comment, sign in
-
Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial - npj Digital Medicine Summary: #DialBetesPlus Study: A recent randomized controlled trial evaluated the effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease. The study aimed to assess the impact of the system on improving outcomes for patients with this condition. #Study Design: The study utilized a randomized controlled trial design to compare the outcomes of patients using DialBetesPlus with those receiving standard care. The trial included a diverse group of participants with diabetic kidney disease. #Intervention: Participants in the intervention group used the DialBetesPlus system, which provided support for self-management of diabetes and kidney disease. The system included tools for monitoring blood sugar levels, tracking medications, and accessing educational resources. #Outcomes: The study evaluated various ai.mediformatica.com #diabetes #change #patients #health #japan #kidneydisease #management #medicine #clinical #digital #behavior #mhealth #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3Wj4zt5)
Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial
nature.com
To view or add a comment, sign in